Skip to main content
Top
Published in: Endocrine Pathology 4/2010

01-12-2010

Depletion of Intranuclear Rodlets in Mouse Models of Diabetes

Authors: Pavel Milman, Accalia Fu, Robert A. Screaton, John M. Woulfe

Published in: Endocrine Pathology | Issue 4/2010

Login to get access

Abstract

Intranuclear rodlets (INRs) are structures present within the nuclei of human insulin-secreting beta cells of the endocrine pancreas. Their physiological significance, and whether they are altered in disease, is unknown. In the present study, the proportion of pancreatic beta cells containing INRs was examined in mouse models of type II diabetes and in a model with improved beta cell function. To gain insights into the molecular regulators of INR formation, mice with a conditional adult beta cell-specific knockout of the serine/threonine protein kinase Lkb1 (Lkb1 adult beta cell knockout (LABKO) mice) were studied. To investigate INR changes in a pathophysiological context, beta cell INRs were examined in two models of human metabolic syndrome: (1) mice maintained on a high-fat diet and (2) leptin-deficient ob/ob mice. The proportion of beta cells containing INRs was significantly reduced in LABKO mice. This reduction was not mediated by two key downstream effectors of Lkb1, mTor and Mark2. High-fat diet regimen reduced beta cell INR frequency by more than 40%, and leptin-deficient ob/ob mice exhibited a dramatically (19-fold) reduced INR frequency relative to wild-type mice. Taken together, our results support the view that INR formation in pancreatic beta cells is a dynamic and regulated process. The substantial depletion of beta cell INRs in LABKO and diabetic mice suggests their relationship to beta cell function and potential involvement in diabetes pathogenesis.
Literature
1.
go back to reference Wajchenberg BL: Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187–218, 2007CrossRefPubMed Wajchenberg BL: Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187–218, 2007CrossRefPubMed
2.
go back to reference Prichett W, Milman P, Gagnon J, Munoz DG, Woulfe J: Intranuclear rodlets in human pancreatic islet cells. Pancreas 35:207–211, 2007CrossRefPubMed Prichett W, Milman P, Gagnon J, Munoz DG, Woulfe J: Intranuclear rodlets in human pancreatic islet cells. Pancreas 35:207–211, 2007CrossRefPubMed
3.
go back to reference Woulfe J, Munoz D: Tubulin immunoreactive neuronal intranuclear inclusions in the human brain. Neuropathol Appl Neurobiol 26:161–171, 2000CrossRefPubMed Woulfe J, Munoz D: Tubulin immunoreactive neuronal intranuclear inclusions in the human brain. Neuropathol Appl Neurobiol 26:161–171, 2000CrossRefPubMed
4.
go back to reference Fu A, Ng AC, Depatie C, Wijesekara N, He Y, Wang GS, Bardeesy N, Scott FW, Touyz RM, Wheeler MB, Screaton RA: Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10:285–295, 2009CrossRefPubMed Fu A, Ng AC, Depatie C, Wijesekara N, He Y, Wang GS, Bardeesy N, Scott FW, Touyz RM, Wheeler MB, Screaton RA: Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10:285–295, 2009CrossRefPubMed
5.
go back to reference Bright NJ, Thornton C, Carling D: The regulation and function of mammalian AMPK-related kinases. Acta Physiol (Oxf) 196:15–26, 2009CrossRef Bright NJ, Thornton C, Carling D: The regulation and function of mammalian AMPK-related kinases. Acta Physiol (Oxf) 196:15–26, 2009CrossRef
6.
go back to reference Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23:833–843, 2004CrossRefPubMed Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23:833–843, 2004CrossRefPubMed
7.
go back to reference Granot Z, Swisa A, Magenheim J, Stolovich-Rain M, Fujimoto W, Manduchi E, Miki T, Lennerz JK, Stoeckert CJ, Jr., Meyuhas O, Seino S, Permutt MA, Piwnica-Worms H, Bardeesy N, Dor Y: LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab 10:296–308, 2009CrossRefPubMed Granot Z, Swisa A, Magenheim J, Stolovich-Rain M, Fujimoto W, Manduchi E, Miki T, Lennerz JK, Stoeckert CJ, Jr., Meyuhas O, Seino S, Permutt MA, Piwnica-Worms H, Bardeesy N, Dor Y: LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab 10:296–308, 2009CrossRefPubMed
8.
go back to reference Islam MS, Loots du T: Experimental rodent models of type 2 diabetes: a review. Methods Find Exp Clin Pharmacol 31:249–261, 2009CrossRefPubMed Islam MS, Loots du T: Experimental rodent models of type 2 diabetes: a review. Methods Find Exp Clin Pharmacol 31:249–261, 2009CrossRefPubMed
9.
go back to reference Lindstrom P: The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal 7:666–685, 2007CrossRefPubMed Lindstrom P: The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal 7:666–685, 2007CrossRefPubMed
10.
go back to reference Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N, Depinho RA: Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol 28:2414–2425, 2008CrossRefPubMed Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N, Depinho RA: Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol 28:2414–2425, 2008CrossRefPubMed
11.
go back to reference Hurov JB, Huang M, White LS, Lennerz J, Choi CS, Cho YR, Kim HJ, Prior JL, Piwnica-Worms D, Cantley LC, Kim JK, Shulman GI, Piwnica-Worms H: Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo. Proc Natl Acad Sci U S A 104:5680–5685, 2007CrossRefPubMed Hurov JB, Huang M, White LS, Lennerz J, Choi CS, Cho YR, Kim HJ, Prior JL, Piwnica-Worms D, Cantley LC, Kim JK, Shulman GI, Piwnica-Worms H: Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo. Proc Natl Acad Sci U S A 104:5680–5685, 2007CrossRefPubMed
12.
go back to reference Kojima Y, Miyoshi H, Clevers HC, Oshima M, Aoki M, Taketo MM: Suppression of tubulin polymerization by the LKB1-microtubule-associated protein/microtubule affinity-regulating kinase signaling. J Biol Chem 282:23532–23540, 2007CrossRefPubMed Kojima Y, Miyoshi H, Clevers HC, Oshima M, Aoki M, Taketo MM: Suppression of tubulin polymerization by the LKB1-microtubule-associated protein/microtubule affinity-regulating kinase signaling. J Biol Chem 282:23532–23540, 2007CrossRefPubMed
13.
go back to reference Woulfe JM, Hammond R, Richardson B, Sooriabalan D, Parks W, Rippstein P, Munoz DG: Reduction of neuronal intranuclear rodlets immunoreactive for tubulin and glucocorticoid receptor in Alzheimer’s disease. Brain Pathol 12:300–307, 2002CrossRefPubMed Woulfe JM, Hammond R, Richardson B, Sooriabalan D, Parks W, Rippstein P, Munoz DG: Reduction of neuronal intranuclear rodlets immunoreactive for tubulin and glucocorticoid receptor in Alzheimer’s disease. Brain Pathol 12:300–307, 2002CrossRefPubMed
14.
go back to reference Muoio DM, Newgard CB: Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9:193–205, 2008CrossRefPubMed Muoio DM, Newgard CB: Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9:193–205, 2008CrossRefPubMed
Metadata
Title
Depletion of Intranuclear Rodlets in Mouse Models of Diabetes
Authors
Pavel Milman
Accalia Fu
Robert A. Screaton
John M. Woulfe
Publication date
01-12-2010
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2010
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-010-9136-5

Other articles of this Issue 4/2010

Endocrine Pathology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine